Sartorius and HOF Sonderanlagenbau Partnership Creates Streamlined Offering of Freeze-Thaw Solutions for Biological Products

Sartorius and HOF Sonderanlagenbau Partnership Creates Streamlined Offering of Freeze-Thaw Solutions for Biological Products

• Integration of HOF horizontal plate freezers into Sartorius Celsius® portfolio simplifies management of drug substance storage and shipping for biopharmaceutical manufacturers.
• Compatible equipment and consumables will allow for quick and streamlined validation of freeze-thaw solutions for customers along with easier purchase and installation.

GOETTINGEN, Germany, December 15, 2021 / B3C newswire / -- Sartorius (DAX: SRT:GR) and HOF Sonderanlagenbau, announced a partnership today to integrate two HOF horizontal plate freeze-thaw units into Sartorius’ portfolio offering customers a full suite of compatible freeze-thaw equipment and consumables. This partnership will enable faster and easier implementation of robust frozen drug substance management platforms through improved validation and purchase support from a single supplier.

“With this partnership, Sartorius continues to strengthen its leading position in the freeze-thaw market,” said Eva Lindskog, Head of Fluid Management Technologies at Sartorius. “The combination of our robust Celsius® single-use containers with market-leading freeze-thaw equipment from HOF will provide our customers with a simplified supply chain for improved management of drug substance.”

A key criterion in the drug substance freeze-thaw process is the ability to reliably control cooling and heating to prevent cryo-concentration. The combination of the new Celsius® consumables, with HOF’s adjustable plate system, provides predictability, robustness, and reproducibility.

Alexander Hof, CEO at HOF Sonderanlagenbau GmbH said, “Our customers that need to freeze during their processes are seeking the best available solutions. The unique combination of our reliable HOF freeze-thaw units and Sartorius’ proven single-use technology consumables portfolio will enable drug manufacturers to progress toward high quality, secure drug substance freezing and thawing for a safer future.”

The partnership builds on Sartorius’ 15-year success in developing proven freeze-thaw solutions for customers worldwide and reinforces the company’s commitment to global access to cold chain product and process innovation.